Clinical Scorecard: The Role of the EASIX Score in Predicting Sinusoidal Obstruction Syndrome and Nonrelapse Mortality in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

At a Glance

Key Highlights

• The EASIX score is calculated as [LDH (U/L) × serum creatinine (mg/dL)] / platelets (10e9/L) and normalized via log2 transformation.
• EASIX score has been validated in adults for predicting HSCT complications including acute graft-versus-host disease, SOS/VOD, transplant-associated microangiopathy, nonrelapse mortality, and overall survival.
• This study retrospectively evaluates the predictive value of the EASIX score for endothelial injury-related complications and NRM specifically in pediatric allo-HSCT patients.

Guideline-Based Recommendations

Diagnosis

• Calculate EASIX score daily from admission before conditioning to day +35 post-HSCT using routine lab parameters (LDH, serum creatinine, platelets).
• Diagnose and grade SOS/VOD according to the European Society for Blood and Marrow Transplantation (EBMT) pediatric criteria.
• Grade acute graft-versus-host disease (aGvHD) using the Glucksberg classification.

Management

• Administer defibrotide promptly for patients diagnosed with SOS/VOD for at least 21 days until resolution.
• Use cyclosporine A and short-term methotrexate for GvHD prophylaxis in matched sibling donors; add antithymocyte globulin for matched unrelated donors.
• Employ posttransplant cyclophosphamide with cyclosporine A and mycophenolate mofetil in haploidentical donor transplants.

Monitoring & Follow-up

• Monitor EASIX score trends throughout the transplant course to assess endothelial injury dynamics.
• Perform regular clinical and laboratory assessments for early detection of SOS/VOD and other endothelial complications.
• Use receiver operating characteristic (ROC) curve analysis to determine optimal EASIX cut-off values for predicting complications.

Risks

• High EASIX scores indicate increased risk of SOS/VOD and nonrelapse mortality.
• Lack of SOS/VOD prophylaxis may increase risk; however, prophylaxis was not administered in this cohort.
• Age may confound EASIX score predictive value; pediatric-specific validation is necessary.

Patient & Prescribing Data

Pediatric patients undergoing allo-HSCT for malignant and nonmalignant diseases

Defibrotide is effective for SOS/VOD treatment; GvHD prophylaxis regimens vary by donor type; antibiotic prophylaxis practices changed during study period.

Clinical Best Practices

• Calculate and monitor EASIX score routinely to identify patients at risk for endothelial complications post-HSCT.
• Apply pediatric-specific diagnostic criteria for SOS/VOD and aGvHD to guide timely intervention.
• Tailor GvHD prophylaxis according to donor type to optimize outcomes.
• Use defibrotide promptly upon SOS/VOD diagnosis to improve resolution rates.
• Conduct comprehensive retrospective and prospective studies to validate EASIX score utility in pediatric HSCT populations.

References

• European Society for Blood and Marrow Transplantation (EBMT) criteria for pediatric SOS/VOD
• Glucksberg classification for acute graft-versus-host disease
• Bacigalupo et al. classification of conditioning regimen intensity
• Luft et al. 2020 study on EASIX in pediatric HSCT